Codiak BioSciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

Codiak BioSciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

Codiak BioSciences, Inc. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.34 million as of 2021-12-31, per its 10-K filed 2022-03-10.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2022-03-10

• 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.34M.
• 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.33M.
• 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.59M.